Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced participation in the Alzheimer’s Association International Conference® 2023 (AAIC®) being held July 16-20, 2023 in Amsterdam, Netherlands and virtually.
- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced participation in the Alzheimer’s Association International Conference® 2023 (AAIC®) being held July 16-20, 2023 in Amsterdam, Netherlands and virtually.
- Participation includes three posters highlighting the company’s next generation therapies for Alzheimer’s disease and a Prothena sponsored symposium.
- Poster #82687, available to view starting Sunday, July 16, 2023
Prothena will present an encore poster presentation of data originally presented at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD) on preclinical data from the PRX012 program comparing a PRX012-surrogate1 (PRX012s) with lecanemab and donanemab. - Poster #74811, available to view starting Sunday, July 16, 2023
On Tuesday, July 18 from 5:45-7:45 PM CEST, Prothena will host an industry sponsored symposium titled “The Voice of the Patient with AD: What Progress in AD Treatment Means to People Living with the Disease”.